Since health insurance approval (May 1st, 2023), administration of T-DXd in patients with unresectable or metastatic HER2-low breast cancer in Japan requires prior assessment of low HER2 expression using a CDx. The gene discussed is ERBB2; the disease is breast carcinoma.